- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Maternal Health Inequities: Improving Access to Postpartum Depression Treatment
Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.
Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for postpartum depression (PPD), became available at the end of last year, offering physicians and patients an effective and more convenient treatment option for managing PPD.
In this episode of Managed Care Cast, hosted by the Center on Health Equity & Access, Douglas Weber, MD, OB-GYN at MomDoc, explained why this therapy has impacted maternal and postpartum care. Previously, treatment for PPD was limited to intravenous (IV) administration of brexanolone (Zulresso) or commonly prescribed antidepressant medications which are not necessarily designed to address the hormonal components of PPD.
